Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference
Myriad Genetics (NASDAQ: MYGN) will present its transformation plan and growth strategies at the Goldman Sachs 2021 Virtual Global Healthcare Conference on June 10, 2021, at 8:50 a.m. EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN) will present its transformation plan and growth strategies at the Goldman Sachs 2021 Virtual Global Healthcare Conference on June 10, 2021, at 8:50 a.m. EST. CEO Paul J. Diaz and CFO Bryan Riggsbee will engage in a fireside chat, which will be available via live audio webcast on the Myriad website. Myriad Genetics specializes in genetic testing and precision medicine, aiming to enhance health through vital genetic insights that support disease prevention, diagnosis, and treatment across various medical fields.
Details
News Market Reaction – MYGN
The recorded move for MYGN in the trading session of this news was +0.99%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, June 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s transformation plan and growth initiatives during a fireside chat at the Goldman Sachs 2021 Virtual Global Healthcare Conference at 8:50 a.m. EST on June 10, 2021.
Diaz will be joined by Bryan Riggsbee, chief financial officer of Myriad Genetics. The presentation will be available via a live audio webcast accessible through the investor section of the Myriad Genetics website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc. is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where genetic testing can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
| Media Contact: Jared Maxwell (801) 505-5027 jmaxwell@myriad.com | Investor Contact: Nathan Smith (801) 505-5067 Nathan.Smith@myriad.com | |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.